The cytotoxic effect of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is limited in many glioma cell lines. However, treatment with TRAIL in combination with subtoxic doses of roscovitine, a specific inhibitor of Cdc2 and Cdk2, induced rapid apoptosis in TRAIL-resistant glioma cells. Roscovitine could sensitize Bcl-2-or Bcl-xL-overexpressing glioma cells, but not human astrocytes, to TRAIL-induced apoptosis, offering an attractive strategy for safely treating resistant gliomas. Treatment with roscovitine significantly inhibited Cdc2 activity, and expression of a dominant-negative Cdc2 mutant sensitized glioma cells to TRAIL-induced apoptosis. While the proteolytic processing of procaspase-3 by TRAIL was partially blocked in U87MG and T98 glioma cells, treatment with roscovitine recovered TRAIL-induced activation of caspases very efficiently in these cells. We found that treatment with roscovitine or expression of a dominant-negative Cdc2 mutant downregulated the protein levels of survivin and XIAP, two major caspase inhibitors. Overexpression of survivin or XIAP attenuated the apoptosis induced by roscovitine and TRAIL. Taken together, these results suggest that downregulation of survivin and XIAP by subtoxic doses of roscovitine contributes to the amplification of caspase cascades, thereby overcoming glioma cell resistance to TRAILmediated apoptosis.
Introduction
Malignant gliomas, the most common brain tumors with high mortality, remain largely incurable despite multimodal treatments including surgical resection, radiotherapy, and chemotherapy (Legler et al., 1999) . The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor family, is capable of inducing apoptosis in tumor cells of diverse origins, but not in most normal cells in vitro, making it an attractive chemotherapeutic candidate (Sheridan et al., 1997; Ashkenazi et al., 1999) . Specifically, TRAIL exhibits selective cytotoxicity for glioma cells versus non-neoplastic astrocytes in vitro (Hao et al., 2001) , and local injections of TRAIL exerted antitumor activity on intracranial human malignant glioma xenografts in athymic mice without attendant neurotoxicity (Roth et al., 1999) . However, glioma cells exhibit a wide heterogeneity in their sensitivity to TRAIL-induced apoptosis, and many glioma cell lines remain resistant to TRAIL even though they express the TRAIL receptor (Knight et al., 2001) . Therefore, the identification of key survival signals responsible for protecting glioma cells from TRAIL-induced apoptosis may aid the design of TRAIL-based combination regimens for the treatment of gliomas. Overexpression of proteins of the inhibitor of apoptosis protein (IAP) family, including survivin and XIAP, has been reported to confer resistance to TRAIL-induced apoptosis in certain cancer cells (Griffith et al., 2002; Ng et al., 2002) . These molecules exert their antiapoptotic effects by interfering with the processing and activities of caspase-3 and -7 (Deveraux and Reed, 1999a) . Both survivin and XIAP are overexpressed in gliomas, and their high expressions correlate with abbreviated patient survival, unfavorable prognosis, resistance to therapy, and accelerated rates of recurrences (Wagenknecht et al., 1999; Chakravarti et al., 2002) .
Roscovitine is an olomoucine-related purine found to inhibit the kinase activity of Cdc2 and Cdk2 kinase (De Azevedo et al., 1997) . Modulation of Cdk activity has been considered an attractive target for cancer therapy, and several Cdk modulators are currently entering into clinical trials (Grant and Roberts, 2003) . However, to date, the results from phase II trials of flavopiridol (a potent Cdk inhibitor) as a single agent have been unsatisfactory, suggesting that it may need to be combined with other drugs (Schwartz et al., 2001; Shapiro et al., 2001) . In the present study, we investigated the possibility of the combined treatment with the Cdk modulator and TRAIL as the potential therapeutics for gliomas. We demonstrate for the first time that TRAIL in combination with subtoxic doses of roscovitine can significantly induce the activation of caspases and apoptosis in TRAIL-resistant glioma cell lines. We assessed the safety of the combined treatment, and found that roscovitine plus TRAIL is cytotoxic to glioma cells that overexpress Bcl-2 or Bcl-xL, while sparing normal astrocytes. In addition, we investigated the underlying mechanisms, and found that roscovitineinduced downregulation of survivin and XIAP may contribute to recovered TRAIL sensitivity.
Results

Subtoxic doses of roscovitine significantly enhanced cell death in TRAIL-resistant human glioma cell lines
The cytotoxic activity of human recombinant soluble TRAIL was tested in four glioma cell lines; T98, U87MG, A172, and U251 ( Figure 1a ). Treatment with 50-200 ng/ml TRAIL induced a limited cell death (o20%) over 48 h, suggesting that these cells are resistant to the apoptotic effects of TRAIL. Next, we tested the cytotoxic effect of roscovitine alone or in combination with TRAIL. Roscovitine alone did not induce any morphological signs of cell death up to 20 mm, although the cellular activity to reduce MTT was slightly decreased at this concentration (Figure 1b) . Cell viability was significantly reduced by the combined treatment both when holding the concentration of TRAIL fixed and varying the concentration of roscovitine and, conversely, when holding the concentration of roscovitine fixed and varying TRAIL. Furthermore, olomoucine, another Cdk inhibitor, also significantly sensitized TRAIL-induced apoptosis, although it required about 5-7-fold higher concentration to achieve a cytotoxicity similar to that of roscovitine (data not shown). We next analysed the effect of roscovitine and TRAIL on long-term survival, by clonogenic assay (Figure 1c ). After treatment with 20 mm roscovitine alone for 7 days, T98 cells showed little change in colony number when compared with the untreated control group, but showed a slight reduction in colony size, possibly due to the inhibition of cellular proliferation. Treatment with 100 ng/ml TRAIL alone did not significantly affect T98 colony size, though colony numbers were slightly decreased. In contrast, combined treatment with roscovitine and TRAIL completely blocked colony formation in T98 cells. Similar results were obtained in U87MG and A172 cells (data not shown). These results demonstrate that the combined treatment with roscovitine and TRAIL effectively induces cell death in these TRAIL-resistant glioma cell lines.
Combined treatment with roscovitine and TRAIL enhanced cell death in glioma cells overexpressing Bcl-2 or Bcl-xL, but not in normal astrocytes Next, we investigated whether combined treatment with roscovitine and TRAIL affects the viability of normal human astrocytes. The astrocytes were resistant to even 500 ng/ml TRAIL, and their viability was not significantly affected by combined treatment with varied concentrations of roscovitine and TRAIL for 48 h (Figure 2a) . These results suggest that sensitizing regimens using roscovitine with TRAIL may be preferentially toxic for glioma cells over normal astrocytes. Bcl-2 or Bcl-xL has been shown to confer resistance to many cytotoxic stimuli in various cancer cells (Adams and Corry, 1998); hence we next investigated whether overexpression of these antiapoptotic proteins could block the sensitizing effect of roscovitine on TRAIL-induced cell death. Stable Bcl-2-or Bcl-xLoverexpressing cell lines were established using U87MG cells (Figure 2b) , and the viability of these cells after treatment with roscovitine and TRAIL for 24 h was assessed by MTT assay (Figure 2c ). TRAIL-induced apoptosis in the presence of roscovitine was not significantly interrupted by overexpression of either Bcl-2 or Bcl-xL. Overexpression of Bcl-2 or Bcl-xL in T98 cells also did not abrogate the sensitizing effect of roscovitine on TRAIL-induced apoptosis (data not shown). These results suggest that combined treatment Glioma cells were treated with roscovitine for 30 min, and further treated with TRAIL for 24 h at the indicated concentrations. MTT assay was performed. Graphs represent the average and standard deviation of three individual experiments. (c) Effect of combined treatment with roscovitine and TRAIL on long-term survival. T98 cells were left untreated or were treated with 100 ng/ml TRAIL and/or 20 mm roscovitine for 7 days. Clonogenic survival was determined by staining colonies with crystal violet, and visualized by a digital camera with roscovitine and TRAIL may have a therapeutic effect on glioma cells overexpressing Bcl-2 or Bcl-xL, which are resistant to many other chemotherapeutic drugs.
Sensitizing effect of roscovitine on TRAIL-induced cell death is associated with an inhibition of Cdc2 kinase activity
The molecular events during the potentiated induction of apoptosis by roscovitine and TRAIL were then investigated. First, we examined the cell cycle progression changes following treatment with roscovitine and/ or TRAIL (Figure 3a ). T98 cells treated with 100 ng/ml TRAIL alone for 10 h showed only 5.4% of cells in G 0 -G 1 ; there was no significant change in cell cycle profile. Treatment with 20 mm roscovitine alone induced a slight shift toward G 2 /M cell cycle arrest (17.8%). However, the combined treatment of TRAIL with roscovitine induced a significant increase in the sub-G 0 /G 1 phase (31.8%). These results provide further evidence that the combined roscovitine plus TRAIL treatment directs glioma cells towards the apoptotic pathway.
Next, we investigated whether the facilitating effect of rosovitine on TRAIL-induced apoptosis is directly associated with the inhibition of Cdc2 and/or Cdk2. T98 cells were treated with 100 ng/ml TRAIL alone, 20 mm roscovitine alone, and 20 mm roscovitine plus 100 ng/ml TRAIL for 10 h. Cdc2 or Cdk2 kinase activity was measured by immunoprecipitation with the respective antibody, followed by a kinase assay on histone H1 as an exogenous conventional substrate (Figure 3b ). Neither Cdc2 nor Cdk2-associated histone H1 kinase Following treatments, cell extracts were prepared and Cdc2 or Cdk2 immune complex kinase assays on histone H1 were performed. Representative results of three independent experiments are shown. Fold change in the respective kinase activity was calculated from liquid scintillation counting of each gel slice. (c) Expression of the DN Cdc2 mutant or DN Cdk2 mutant enhanced TRAIL-induced apoptosis. U87MG cells were transiently transfected with plasmids encoding DN Cdc2 mutant, DN Cdk2 mutant or pcDNA3. After 24 h, cells were treated with TRAIL for another 24 h, or left untreated. Cellular viability was assessed using calcein-AM and ethidium homodimer-1. The data represent one of two independent experiments with consistent results activity was affected by the treatment with TRAIL alone. Treatment with roscovitine alone or roscovitine plus TRAIL significantly decreased Cdc2 kinase activity without any significant effect on Cdk2 activity. These results suggest that the sensitizing effect of roscovitine on TRAIL-induced cell death may be more directly associated with inhibition of Cdc2 activity rather than Cdk2 in these cells.
We then examined whether introduction of a dominant-negative (DN) Cdc2 mutant could mimic the sensitizing effect of roscovitine on TRAIL-induced apoptosis ( Figure 3c ). U87MG cells were treated with TRAIL after transient transfection with plasmids encoding a DN Cdc2 mutant, DN Cdk2 mutant or control pcDNA3, and cellular viability was measured by staining with calcein-acetoxymethyl ester (calcein-AM) AM and ethidium homodimer (Etd-1), which detect live and dead cells, respectively. TRAIL treatment significantly enhanced death in cells transfected with the DN Cdc2 or DN Cdk2 mutants, compared with the cells transfected with pcDNA3, while transiently transfected DN Cdc2 or DN Cdk2 mutants alone slightly decreased the viability. These results suggest that inhibition of either Cdc2 or Cdk2 kinase activity can facilitate TRAIL-induced apoptosis in these TRAIL-resistant glioma cells, although subtoxic doses of roscovitine inhibited Cdc2 kinase activity more than Cdk2.
Critical role of caspases in cell death by the combined treatment with roscovitine and TRAIL
We examined whether the roscovitine-facilitated TRAIL-induced cell death of glioma cells was mediated through caspases ( Figure 4a ). T98 cells were treated with 20 mm roscovitine for 10 h, or 100 ng/ml TRAIL alone, or pretreated with roscovitine (30 min), followed by TRAIL for the indicated times. Treatment with 20 mm roscovitine alone for 10 h did not induce any proteolytic processing of caspases. In response to TRAIL, the 32-kDa procaspase-3 was partially cleaved to a 20-kDa intermediate form after 2 h, but further cleavage into the active p17 subunit was not detected, nor were other caspase-processing events. However, treatment with roscovitine plus TRAIL induced the cleavage of caspase-3 into the p20 intermediate form at 2 h, and its subsequent cleavage into the active p17 subunit after 4 h. Caspase-2, -7, -8, and -9 were also progressively processed after 4 h of the combined treatment. We further assessed the cleavage of several key death substrates that indicate the activation of caspases, including PARP (substrate for caspase-3, -7), FAK (caspase-3), DFF-45 (caspase-3), and Bid (caspase-8) (Earnshaw et al., 1999) . In parallel with the proteolytic processing of caspases, these substrate proteins were progressively degraded from 4 h after the combined treatment, whereas they were not degraded following treatment with TRAIL or roscovitine alone ( Figure 4b ). Similar but slower activation patterns of caspases in U87MG cells were observed in response to roscovitine plus TRAIL, consistent with the slower apoptotic progression in this cell line compared to that in T98 cells (Figure 4a -c). These results suggest that TRAIL resistance in these glioma cell lines may result from a proteolytic processing blockade of procaspase-3, and a failure in the subsequent caspase amplification cascades.
To ascertain the role of caspase(s) in the roscovitine potentiation of TRAIL-induced apoptosis, we tested the effects of specific caspase inhibitors. Pretreatment of U87MG cells with z-VAD-fmk, a pancaspase inhibitor, significantly blocked the cell death induced by roscovitine and TRAIL ( Figure 5a ). A specific inhibitor of caspase-8, z-IETD-fmk, blocked the combined treatment-induced apoptosis more potently than z-DEVDfmk (inhibitor of caspase-3) or z-LEHD-fmk (caspase-9). Similar results were obtained in the experiments using T98 cells (data not shown). Overexpression of the viral caspase-8 inhibitor CrmA has been reported to block TRAIL-induced apoptosis (Zhou et al., 1997) . We found that overexpression of CrmA in U87MG cells efficiently inhibited the activation of caspase-8 by the combined treatment, as assessed by in vitro protease assay using IETD-AFC as a substrate (Figure 5c ). In the Sensitization of TRAIL-induced apoptosis by roscovitine EH Kim et al cells overexpressing CrmA, the proteolytic processing of both Bid, the substrate protein of caspase-8, and procaspase-3 was completely blocked (Figure 5d ). Roscovitine-facilitated TRAIL-induced apoptosis was also blocked in these cells overexpressing CrmA (Figure 5e ), further demonstrating the critical role of caspases in apoptosis following the combined treatment.
Combined treatment with roscovitine and TRAIL reduced the expression of multiple proteins associated with cell survival
Recently, radiation or chemotherapeutic agents have been shown to upregulate the expression of the death receptors DR4 or DR5, which results in enhanced TRAIL-induced apoptosis (Gibson et al., 2000; Nagane et al., 2000) . We therefore examined the effect of roscovitine on the surface expression of DR4 and DR5 by flow cytometry (Figure 6a ). Cell membrane expression of these death receptors in U87MG cells was not significantly altered by treatment with roscovitine. Neither DcR1 nor DcR2 protein levels were changed in U87MG cells treated with roscovitine. Furthermore, Figure 5 Critical role of caspases in apoptosis induced by the combined treatment with roscovitine and TRAIL. (a) Effect of the inhibition of the specific caspase(s) on roscovitine-facilitated TRAIL-induced apoptosis. U87MG cells were treated with caspase-specific tetrapeptide inhibitors at the indicated concentrations for 30 min, and then further treated with roscovitine (20 mm) and TRAIL (100 ng/ml). Cellular viability was assessed by MTT assay. The graph represents one of two independent experiments with consistent results. z-VAD-fmk, z-DEVD-fmk, z-IETD-fmk, and z-LEHD-fmk are inhibitors of pan-caspases, caspase-3, caspase-8, and caspase-9, respectively. (b) Immunoblot of CrmA expression in U87MG sublines stably transfected with control vector pcDNA3 alone or with the CrmA cDNA. (c) Effect of CrmA overexpression on the combined treatment-induced caspase-8 activity. U87MG cells or the stable cell lines overexpressing CrmA were treated with or without roscovitine (20 mm) plus TRAIL (100 ng/ml) for 16 h. Caspase activity cleaving IETD-AFC substrate was determined by caspase-8 fluorescent assay. Values from each treatment group are expressed as a percentage relative to the untreated control U87MG cells (100%). The data represent the means of triplicate determinations. (d) Effect of CrmA overexpression on Bid and procaspase-3 protein levels following treatment with roscovitine and TRAIL. The sublines overexpressing CrmA were treated with roscovitine and TRAIL in combination, and cell extracts were prepared for Western blotting. (e) Overexpression of CrmA blocks roscovitine-facilitated TRAILinduced apoptosis. The sublines overexpresing CrmA were treated with roscovitine plus TRAIL for 24 h, and cellular viability was measured by MTT assay. Data represent means of triplicate determinations Recent reports have demonstrated that there are several intracellular proteins capable of inhibiting death receptor-mediated apoptosis when present at sufficient levels (Adams and Corry, 1998; Tschopp et al., 1998; Deveraux and Reed, 1999a; Thakkar et al., 2001; Griffith et al., 2002; Ng et al., 2002) . We therefore examined the expression of several apoptosis-related proteins. Expression of Bcl-2, Bcl-xL, c-IAP2, and FLIP was unchanged in these cells. In contrast, in T98 and U87MG cells treated with roscovitine and TRAIL, the protein levels of survivin, XIAP, and the activated form of Akt were significantly decreased during apoptosis (Figure 7a ). Both XIAP and Akt have been recently reported to be substrates of caspases (Deveraux et al., 1999b; Rokudai et al., 2000) . Therefore, we investigated whether a decrease in these protein levels during apoptosis by the combined treatment was associated with the enhanced activities of caspases (Figure 7b ).
Overexpression of CrmA completely blocked the downregulation of Akt by the combined treatment, and considerably (but not completely) blocked the downregulation of XIAP. These results suggest that another noncaspase control mechanism may exist for the regulation of XIAP levels, while reduction of Akt by the combined treatment was exclusively caused by caspases. Interestingly, survivin was still downregulated in CrmA-overexpressing cells treated with roscovitine and TRAIL in combination. Therefore, we next examined whether roscovitine itself downregulates the expression of survivin or XIAP. Treatment with roscovitine alone dramatically reduced survivin protein levels in a dose-and time-dependent manner, while the same treatment reduced XIAP protein level to a lesser extent (Figure 8a) . RT-PCR analysis demonstrated that mRNA levels of XIAP but not survivin were significantly downregulated by roscovitine (Figure 8b ), suggesting that roscovitine modulates XIAP expression at the transcriptional level, but survivin expression at the post-transcriptional level. Recently, survivin has been shown to be regulated by the ubiquitin-proteasome pathway in a cell cycle-dependent manner (Zhao et al., 2000) . Therefore, we tested the effect of MG132, a proteasome inhibitor, on roscovitine-induced downregulation of survivin. Reduction of the survivin protein level by roscovitine was alleviated by treatment with MG132 in a dose-dependent manner (Figure 8c ), demonstrating the involvement of proteasome pathway in its downregulation. Transfection of U87MG cells with the plasmid encoding a DN Cdc2 mutant but not pcDNA3 induced the reduction in survivin and XIAP protein level (Figure 8d ), further confirming that downregulation of survivin and XIAP by roscovitine is mediated by the inhibition of Cdc2 activity. To investigate whether downregulation of survivin or XIAP by roscovitine is critical to trigger TRAIL-induced apoptosis, we established the stable cell lines overexpressing survivin or XIAP (Figure 8e ). Not only in the cells overexpressing survivin but also in the cells overexpressing XIAP, apoptosis induced by roscovitine and TRAIL was attenuated considerably, but not completely (Figure 8f ). These results suggest that survivin and XIAP may be involved in resistance against TRAIL-induced apoptosis in glioma cells. Taken together, our results demonstrate that roscovitine-induced downregulation of survivin and XIAP, the caspase inhibitors, may trigger the completion of procaspase-3 processing begun by TRAIL. Further degradation of XIAP by the activated caspase-3 may amplify the various caspase cascades, leading to cell death.
Discussion
The resistance of gliomas to current treatment protocols still remains a major concern in cancer therapy. The development of malignant gliomas involves the accumulation of multiple genetic changes, including the mutations in the p53, retinoblastoma pathway, and S-phase entry control genes (Sehgal, 1998) . A gain of proximal 5q, which includes the genes for cyclin B1 (CCNB1) and cyclin H (CCNH), leads to a significant increase of the growth rate of malignant gliomas (Weber et al., 2001 ). These results suggest that cyclins that activate Cdc2 may play a role in glioma tumorigenesis. Due to the multitude factors involved in astrocytoma pathogenesis, the simultaneous targeting of several pathways may show greater efficacy in astrocytoma therapy. The efficiency of TRAIL-induced apoptosis in malignant gliomas is variable, and many glioma cell lines are either partially or completely resistant to this ligand (Rieger et al., 1998; Hao et al., 2001; Knight et al., 2001) . In an attempt to identify a sensitizing agent capable of overcoming TRAIL resistance in glioma cells, we investigated the ability of roscovitine, an inhibitor of Cdc2 and Cdk2, to modulate TRAILinduced apoptotic sensitivity. When tested separately, roscovitine and TRAIL had limited toxicity to human glioma cells, and roscovitine plus TRAIL was not cytotoxic to normal astrocytes. However, subtoxic doses of roscovitine effectively restored the sensitivity of glioma cells to TRAIL-induced apoptosis, resulting in the permanent loss in clonogenicity. Furthermore, roscovitine-facilitated TRAIL-induced apoptosis was not interrupted by Bcl-2 and Bcl-xL, two antiapoptotic proteins that often confer resistance to chemotherapeutic agents. Since development of the effective therapeutic strategies that kill only tumor cells has important clinical implications in cancer therapy, the combination of roscovitine and TRAIL seems a promising strategy for treating malignant gliomas. It remains to be determined whether this combination increases the selectivity toward glioma cells in vivo. In addition, comprehensive studies will be necessary to evaluate the sensitivity of the diverse cell populations within the human brain to roscovitine and TRAIL. Although the present study focused on cultured glioma cells, we also found that roscovitine reproducibly enhanced TRAIL-induced apoptosis in many other cancer cell lines, including Hep3B, Huh-7, and HeLa cells (unpublished results), suggesting the potential applicability of this combined treatment to various types of tumor cells. Since roscovitine significantly strengthened the antitumor activity of TRAIL even at low TRAIL concentrations, roscovitine may additionally be used to enhance the efficacy of TRAIL-based cancer therapies by reduction of necessary TRAIL dosages, and the exposure time required for inhibition of tumor growth.
The Bcl-2 family proteins inhibit apoptosis by preventing the release of mitochondrial intermembrane proteins, such as cytochrome c (Kroemer and Reed, 2000) . In our study, overexpression of Bcl-2 or Bcl-xL in U87MG or T98 cells was unable to block the apoptosis induced by roscovitine and TRAIL in combination. In contrast, CrmA overexpression completely blocked roscovitine-facilitated TRAIL-induced apoptosis. CrmA is a relatively potent inhibitor of procaspase-8-induced processing of procaspase-3, but is far less effective against the cytochrome c-mediated activation of procaspase-3 (Zhou et al., 1997) . These results suggest that the death receptor signaling pathway via caspase-8 may be more important than the mitochondrial pathway via caspase-9 in cell death induced by the combined treatment. Since IAPs such as survivin, XIAP, c-IAP1, and c-IAP2 block apoptosis at the effector phase, a point where multiple signaling pathways converge, strategies targeting IAPs to remove their inhibitory effects seem to be potentially useful to overcome the resistance of cancer cells to anticancer drugs (Deveraux and Reed, 1999a) . Owing to the unique properties of survivin, many researchers have questioned whether survivin functions in cytoprotection, as do other mammalian IAPs, or whether it is more closely involved in the regulation of cell division, as are BIR-containing IAPs in yeast and C. elegans (Altieri, 2003) . Although this question remains open, many studies have established the role of survivin in apoptosis, and suggested that its antiapoptotic function is related to its ability to directly or indirectly inhibit caspases (Zaffaroni and Daidone, 2002) . The expression of survivin can be controlled at the transcriptional level though cell-cycle-dependent element/cell-cycle gene homology region (CDE/CHR) boxes, which are located in the proximal survivin promoter (Badie et al., 2000) . Furthermore, polyubiquitylation of survivin and its proteasome-dependent destruction have been demonstrated in interphase cells, and mitotic phosphorylation of survivin on Thr34 by Cdc2-cyclin B1 has been associated with increased protein stability at metaphase (Zhao et al., 2000; O'Connor et al., 2002) . In our study, survivin protein levels were rapidly and dramatically reduced following treatment with roscovitine, while survivin mRNA levels were not significantly reduced. Treatment with MG132, a proteasome inhibitor, blocked roscovitine-mediated decline in survivin protein levels, suggesting the involvement of the proteasomal pathway in its downregulation. Since both treatment with roscovitine and ectopic expression of a DN Cdc2 mutant significantly decreased the survivin protein level, a generation of unphosphorylated survivin by the decreased Cdc2 activity may be particularly susceptible to proteasomal degradation. Overexpression of survivin attenuated the cell death induced by roscovitine and TRAIL, suggesting that the sensitizing effect of roscovitine on TRAILinduced apoptosis may be associated with the modulation of surivin protein levels. Of the known human IAPrelated proteins, XIAP is the most potent inhibitor of apoptosis that binds to and inhibits caspase-9, -7, and -3 activities (Deveraux and Reed, 1999a) . There is also evidence that the E3 ligase activity embedded in the RING domain of XIAP may contribute to cytoprotection, and facilitate proteasome-dependent destruction of bound caspase-3 (Suzuki et al., 2001) . XIAP has been associated with TRAIL resistance in melanoma cells. Proteolytic processing of procaspase-3 into the active p17 subunit and degradation of ICAD and PARP were blocked in TRAIL-resistant melanoma cell lines. Instead, the p20 fragment (the intermediate form of procaspase-3) was associated with XIAP after exposure to TRAIL (Zhang et al., 2001 ). Similar to their results, we detected the p20 fragment following treatment with TRAIL both in U87MG and in T98 cells, which are resistant to TRAIL-induced apoptosis. However, any further cleavage into the active p17 subunit was not detected. On the other hand, combined treatment with roscovitine and TRAIL dramatically reduced XIAP protein levels in these cells. Since XIAP has been reported to be a substrate of caspase-3 and -7 (Deveraux et al., 1999b) , it is possible that the observed decrease in XIAP content could be a consequence of caspasemediated processing. In our study, overexpression of CrmA considerably (but not completely) blocked the downregulation of XIAP by the combined treatment, suggesting that caspases are at least partially responsible. Moreover, XIAP protein levels were slightly downregulated by treatment with roscovitine, possibly through its transcriptional control. Taken together, these results suggest that XIAP may be downregulated primarily by roscovitine alone, and secondarily by caspases activated during roscovitine-facilitated TRAIL-induced apoptosis. In the combined therapy, reduction of XIAP protein levels by roscovitine may permit the complete autoprocessing cascade of the p20 intermediate form, generated by TRAIL, into the p17 active subunit. Subsequently, caspase-3 activated at the initial phase can cleave XIAP further to allow amplification of the caspase cascades. The fact that roscovitine up to 20 mm alone was unable to induce apoptosis efficiently in these cells suggests that a marked downregulation of survivin and a slight downregulation of XIAP by roscovitine may not be sufficient to trigger the activation of caspases. The partial proteolytic processing of procaspase-3 into the p20 fragment, the priming event by TRAIL, as well as downregulation of survivin and XIAP by roscovitine, may be required for the accelerated apoptosis in these glioma cells.
Taken together, we propose that downregulation of the IAP family of proteins such as survivin and XIAP may be one mechanism by which roscovitine overcomes barriers to TRAIL-induced apoptosis of glioma cells. Thus, treatment with TRAIL in combination with subtoxic doses of roscovitine may provide an effective treatment strategy for safely treating resistant gliomas.
Materials and methods
Chemicals and antibodies
Recombinant human TRAIL/Apo2 ligand was from Alexis Biochemicals (Coger, Paris, France). Calcein-AM and Etd-1 were from Molecular Probe (Eugene, OR, USA). Roscovitine, z-VAD-fmk, z-IETD-fmk, z-DEVD-fmk, and z-LEHD-fmk were from Calbiochem (San Diego, CA, USA). The following antibodies were used: anticaspase-8, caspase-3, caspase-7, survivin, FLIP, and XIAP (Stressgen, BC, Canada); anticaspase-9, caspase-2, Rb, Lamin B, FAK, Bcl-2, and Bcl-xL (Santacruz Biotechnologies, Santacruz, CA, USA); antiphospho-Akt, Akt, and Bid (Cell Signaling, Beverly, MA, USA); anti-Flag M2 and fluorescein isothiocyanate (FITC)-conjugated anti-goat IgG (Sigma, St Louis, MO, USA); antiCrmA (BD Pharmingen, San Diego, CA, USA); DFF-45 (Transduction Lab., Lexington, KY, USA); anti-DR4, -DR5, -DcR1, and -DcR2 (R&D systems, Inc., USA); anti-rabbit IgG HRP, mouse IgG, and goat IgG (Zymed Laboratories, Inc., South San Francisco, CA, USA).
Culture of glioma cell lines and normal human astrocytes
The human malignant glioma cell lines U87MG, T98G, A172, and U251MG were cultured in Dulbecco's modified Eagle's medium (DMEM) (GIBCO-BRL, Life Technologies, NY, USA), supplemented with 10% fetal bovine serum and antibiotics (GIBCO-BRL, Life Technologies, NY, USA). The primary cultures of normal human astrocytes were prepared from 14-week-gestation fetal cerebrum tissues, as described previously (Kim, 1985; Kim et al., 1986) . Human astrocyte cultures were subcultured in DMEM containing 10% fetal bovine serum every 2 weeks, and cell cultures with passage number less than 5 were used in the present study. Immunofluorescence study indicated that more than 99% of the cells expressed glial fibrillary acidic protein (GFAP)-positive immunoreactivity, a cell type-specific marker for astrocytes. Permission to use human brain tissues for research was granted by the Ethics Committee of the University.
Measurement of cellular viability
Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells (5 Â 10 3 cells/well) were plated in a 96-well plate. Following treatment, the MTT stock solution (5 mg/ml in PBS) was added to the medium, and incubated with cells at 371C for 3 h to allow cellmediated reduction of MTT. The absorbance was measured at 540 nm in a microtiter plate reader. Alternatively, the cell viability was assessed by double labeling of cells with 2 mm calcein-AM and 4 mm Etd-1. The calcein-positive live cells and Etd-1-positive dead cells were visualized using a fluorescence microscope (Nikon Diaphot 300, Japan).
Clonogenic assay
Cells (1 Â 10 3 ) were seeded in a six-well plate at a single cell density, and followed by treatment with 100 ng/ml TRAIL and/or 20 mm roscovitine for 7 days. Clonogenic survival was determined by staining colonies using crystal violet, and visualized by a digital camera.
Immunoblotting
Cells were washed in PBS and lysed in boiling sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (62.5 mmol/l Tris (pH 6.8), 1% SDS, 10% glycerol, and 5% b-mercaptoethanol). The lysates were boiled for 5 min, separated by SDS-PAGE, and transferred to an Immobilon membrane (Millipore, Bedford, MA, USA). After blocking nonspecific binding sites for 1 h by 5% skim milk, the membranes were incubated for 2 h with specific Abs. The membranes were then washed three times with TBST, and incubated further for 1 h with horseradish peroxidase-conjugated anti-rabbit, -mouse or -goat antibody. Visualization of protein bands was accomplished using ECL (Amersham Life Science, Buckinghamshire, UK).
Cell cycle analysis
DNA content was assessed using Cell Cycle TEST PLUS DNA TM reagent kit (Becton Dickinson and Co., San Jose´, CA, USA), according to the manufacturer's instruction, and analysed in a FACS sorter (Becton Dickinson and Co.).
Immune complex kinase assay
After treatment of T98G cells as indicated, cells were lysed in buffer A (1% Nonidet P-40, 50 mm Tris-HCl (pH 8.0), 150 mm NaCl, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 20 mm NaF, 1 mm Na 3 VO 4 , 10 mg/ml PMSF) at 41C for 15 min. Cell lysates were cleared by centrifugation at 13 000 r.p.m. for 15 min. Protein concentrations were quantitated by Bio-Rad protein assay. A total of 500 mg of protein was used for each immunoprecipitation. Cdc2 and Cdk2 in cell extracts were incubated with the specific antibody (1 mg/reaction) for 3 h at 41C. Protein A/G-agarose (15 ml; Oncogene Research Products, Cambridge, MA, USA) was added into the mixture, which was then further incubated for 1 h. Immune complexes were centrifuged at 2500 r.p.m. for 5 min, and the precipitates were washed three times with buffer A and twice with kinase buffer (50 mm Tris-HCl (pH 7.5), 10 mm MgCl 2 , 1 mm DTT). Cdk kinase assays on histone H1 were performed by mixing the respective immune complexes with 5 mg of histone H1 and 10 mCi of [m-32 P]ATP in 30 ml of kinase buffer. The kinase reaction was performed at 301C for 30 min, and then terminated with 2 Â SDS-PAGE sample buffer. The reaction mixtures were resolved by SDS-PAGE analysis. Gels were stained with Coomassie Blue staining solution and dried. The extent of phosphorylation was measured by liquid scintillation counting of the gel slices of each substrate.
Transient transfection with DN Cdc2 or DN CDK2 mutant U87MG cells were plated into 24-well plates at 5 Â 10 4 cells/ well. After 24 h, cells were transfected with DN Cdc2 mutant and DN Cdk2 mutant (Van den Heuvel and Harlow, 1993) , kindly provided by Professor E Harlow (Massachusetts General Hospital Cancer Center), at the indicated concentrations, using Lipofectamine Plus reagent (Gibco BRL, Grand Island, NY, USA), following the manufacturer's instructions. After incubation of the transfected cells for 24 h, cells were further treated or not treated with 100 ng/ml TRAIL for 24 h. Transfection efficiency, which was assessed using the plasmid encoding green fluorescence protein, reached about 70% in U87MG cells in these experiments. Cellular viability was assessed using calcein-AM and Etd-1 as described above.
Establishment of Bcl-2-, Bcl-xL-, CrmA-, XIAP-or survivin-overexpressing U87MG stable cell line U87MG cells were transfected with a mammalian expression vector containing Flag-tagged bcl-2 cDNA and bcl-xL (Huang et al., 1997) , kindly provided by A Strasser (The Walter and Eliza Hall Institute of Medical Research, Australia), with a vector containing CrmA cDNA (Tewari et al., 1995) , kindly provided by Professor VM Dixit (University of Michigan Medical School), and a vector containing Myc-tagged XIAP (Nomura et al., 2003) , kindly provided by Professor T Nomura (Oita Medical University, Japan). Stable cell lines overexpressing Bcl-2 or Bcl-xL were selected with changes of fresh media containing puromycin (4 mg/ml). Overexpression of Bcl-2 or Bcl-xL in the stable cell lines was analysed by Western blotting using anti-Flag antibody. Stable cell lines overexpressing CrmA or XIAP were selected with changes of media containing G418 (500 mg/ml). Overexpression of CrmA in the stable cell lines was analysed by Western blotting using anti-CrmA antibody, and overexpression of XIAP in the stable cell lines was analysed using anti-c-Myc antibody (9E10). To establish the stable cell lines overexpressing survivin, U87MG cells were cotransfected with a flag/survivin fusion protein expression vector (Kobayashi et al., 1999) , kindly provided by Professor T Tokuhisa (Chiba University Graduate School of Medicine, Japan), and pcDNA3. The transfected cells were selected with changes of media containing G418 (500 mg/ml), and overexpression of survivin was analysed by Western blotting using an anti-Flag antibody.
Activity assay of caspase-8
Cell pellets obtained from 2 Â 10 6 cells were resuspended in 50 ml of chilled lysis buffer, and incubated on ice for 10 min. The cell lysates were centrifuged at 12 000 r.p.m. at 41C for 10 min, and the supernatants were collected. The reaction buffer (50 ml) containing 10 mm dithiothreitol and 5 ml of 1 mm IETD-AFC (7-amino-4-trifluoromethyl coumarin) substrate was added to the supernatants and incubated at 371C for 2 h in the dark. The absorbance of each sample was measured at 400 nm excitation and 505 nm emission wavelength with a microtiter plate reader.
Flow cytometry of death receptors
Cells were analysed for the surface expression of DR4, DR5, DcR1, and DcR2 by indirect staining with primary goat antihuman DR4 and DR5 (R&D systems), followed by FITCconjugated rabbit anti-goat IgG (Sigma). Briefly, cells (1 Â 10 6 ) were stained with 200 ml PBS containing saturating amounts of anti-DR4, anti-DR5, anti-DcR1, or anti-DcR2 on ice for 30 min. After incubation, cells were washed twice, and reacted with FITC-conjugated rabbit anti-goat IgG on ice for 30 min. After washing with PBS, the expression of these death receptors was analysed by a FACS sorter (Becton Dickinson and Co.).
Semiquantitative RT-PCR analysis
Total RNA was extracted from U87MG cells using the RNAzolB reagent protocol (TEL-TEST, Inc., TX). To measure the abundance of survivin and XIAP, mRNA primers were tested with different primer concentrations and different cycles to avoid mRNA amplification near the plateau and saturation. Conditions for final analysis were chosen when amplification of mRNA was in the middle of the exponential amplification phase for all roscovitine concentrations tested. Total RNA (1 mg) from each treatment group was used for the preparation of first-strand cDNA by reverse transcription. The RNA samples were incubated (301C for 10 min, 421C for 30 min, and 991C for 5 min) with 1 Â buffer, MgCl 2 (5 mm), oligo dT-adapter primer (0.125 mm), deoxynucleotide triphosphate (1 mm), and avian myeloblastosis virus reverse transcriptase (0.25 U) (TaKaRa Korea Medical Inc., Korea) in 20 ml of a reaction mixture. Human survivin mRNA was amplified using the sense primer 5 0 -cagatttgaatcgcgggaccc-3 0 and the antisense primer 5 0 -CCAGAGTCTGGCTCGTTCT-CAG-3 0 (corresponding to a 206-bp region of survivin cDNA sequence (5-212 bp; Gazzaniga et al., 2003) . For XIAP, expression of the gene was determined by amplification of a 389-bp region of the XIAP cDNA sequence (973-1361 bp; Asselin et al., 2001) . Each reaction mixture contained 1 Â buffer, template, MgCl 2 (1 mm), primers (0.1 mm each), and Taq polymerase (1 U) (TaKaRa Korea Medical Inc., Korea). The PCR cycling conditions (30 cycles) chosen were as follows:
(1) 30 s at 941C, (b) 1 min at 601C (for survivin), 591C (for XIAP), and (c) 1 min at 721C, with a subsequent 10 min extension at 721C. Reaction products were analysed on 1.3% agarose gels. The bands were visualized by ethidium bromide staining.
Abbreviations TRAIL, TNF-related apoptosis-inducing ligand; GFAP, glial fibrillary acidic protein; PBS, phosphate-buffered saline; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PAGE, polyacrylamide gel electrophoresis; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; DN, dominant negative; FLIP, FLICE-inhibitory protein; IAP, inhibitor of apoptosis; XIAP, X-chromosome-linked IAP; FITC, fluorescein isothiothyanate; RT-PCR, reverse transcriptase-polymerase chain reaction.
